Tallahassee Sun

Congressman Neal Dunn and House Energy & Commerce Health Subcommittee Chairman Brett Guthrie have raised concerns about the Biden Administration's attempt to utilize march-in authority for government price controls. Congressman Dunn stated, "Prescription drug prices and the cost of life-saving treatments are out of control, but government price controls are not the answer." He emphasized the negative impact of such controls on innovation and medical discoveries.

Congressman Guthrie echoed these sentiments, criticizing the administration's overreach in the prescription drug marketplace. He called on President Biden to withdraw the proposal and work with House Republicans to lower drug prices while encouraging investments in future cures.

The Federal Trade Commission explained that under the Bayh-Dole Act, the government can intervene on patents for inventions developed with taxpayer funds. The letter sent by Dunn and Guthrie urges the U.S. Department of Health and Human Services to investigate the administration's motives in attempting to redefine the terms of the Bayh-Dole Act.

The lawmakers are concerned that the Biden Administration's approach, focusing on the product's cost, will deter investment in biotechnology innovation. They warned that such actions could have negative consequences for patients' access to life-saving medications.